- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04975867
Gerenciamento Adjunto de Temperatura Alvo em Intoxicação Aguda Grave por Monóxido de Carbono
Gerenciamento de temperatura direcionado combinado com oxigenoterapia hiperbárica em intoxicação aguda grave por monóxido de carbono: ensaio clínico randomizado controlado multicêntrico (estudo TTM-COHB)
This randomized trial will investigate important neurocognitive clinical outcomes of patients with acute severe carbon monoxide poisoning (ASCOP) randomized to receive either therapeutic hypothermia or normothermia combined with hyperbaric oxygen therapy (HBO).
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
CO-poisoned patients are identified by medical history and carboxyhemoglobin (CO-Hb) value >5% (>10% in smokers). Patients presenting with acute CO poisoning will receive one HBO. ASCOP is defined as mental status showing response to painful stimulus or unresponsiveness requiring intubation for airway protection and ventilation support at the emerency department, and persistence of depressed mental status despite the HBO. After HBO treatment, eligible patients who provide consent will be randomly allocated to receive hypothermia, or normothermia treatment administered in a open label fashion except for blinding of outcome assessor.
Outcome measures will be administered at 1 month and 6 months after CO exposure. In addition, we will examine the differences in serum markers and mortality between the hypothermia and normothermia groups.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Gangwon-do
-
Wŏnju, Gangwon-do, Coréia do Sul, 26426
- Wonju Severance Christian Hospital
-
-
Incheon
-
Incheon, Incheon, Coréia do Sul, 22332
- Inha University Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- ≥ 19 years.
- Patients who received HBO within 24 hours for acute CO poisoning.
- Patients who meet the definition of ASCOP (Patients incapable verbal obey after HBO).
- Signed informed consent prior to study entry.
Exclusion Criteria:
- Cardiac arrest before HBO
- Previous neurocognitive disorders
- Life-threatening underlying disease (ex: advanced cancer)
- Evidence of co-ingestion of sedative or hypnotics confirmed by intravenous flumazenil administration or history taking at the emergency department
- Absolute contraindication for TH (active severe bleeding and profound shock not controlled by vasoactive drugs)
- No admission
- The significant co-ingested drug levels, which are alter the consciousness, is confirmed from the drug analysis lab
- Pregnancy
- Burns
- More than moderate burn or Inhalation burn
- Burns complicated by other trauma
- Electrical burn
- Burns in high risk patients (Patients with chronic underlying diseases (i.e DM, ESRD, liver cirrhosis, etc) which may cause delays or aggravate the wound healing)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Hypothermia group
Hypothermia group is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After therapeutic hypothermia ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours. |
Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours. |
|
Comparador Ativo: Normothermia group
For normothermia group, it will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent. |
Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Main neurocognitive outcome
Prazo: At 6 months after CO poisoning
|
Global Deterioration Scale [range 1 - 7 (worst score)] |
At 6 months after CO poisoning
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Neurocognitive outcome
Prazo: At 1 month after CO poisoning
|
Global Deterioration Scale [range 1 - 7 (worst score)] |
At 1 month after CO poisoning
|
|
Cerebral Performance Category
Prazo: At 1 month and 6 months after CO poisoning
|
Cerebral Performance Category [range 1 - 5 (worst score)] |
At 1 month and 6 months after CO poisoning
|
|
modified Rankin scale
Prazo: At 1 month and 6 months after CO poisoning
|
modified Rankin scale [range 0 - 6 (worst score)] |
At 1 month and 6 months after CO poisoning
|
|
Glasgow outcome scale
Prazo: At 1 month and 6 months after CO poisoning
|
Glasgow outcome scale [range 1 (worst score) - 5] |
At 1 month and 6 months after CO poisoning
|
|
mini-mental status exam
Prazo: At 1 month and 6 months after CO poisoning
|
mini-mental status exam |
At 1 month and 6 months after CO poisoning
|
|
Korean version of the Modified Barthel Index
Prazo: At 1 month and 6 months after CO poisoning
|
Korean version of the Modified Barthel Index |
At 1 month and 6 months after CO poisoning
|
|
Mortality in intensive care unit
Prazo: Through study completion, an average of 6 months
|
Number of participants with mortality in intensive care unit |
Through study completion, an average of 6 months
|
|
Mortality in intensive care unit
Prazo: Through study completion, an average of 6 months
|
Rate of participants with mortality in intensive care unit |
Through study completion, an average of 6 months
|
|
In-hospital mortality
Prazo: Through study completion, an average of 6 months
|
Number of participants with in-hospital mortality |
Through study completion, an average of 6 months
|
|
In-hospital mortality
Prazo: Through study completion, an average of 6 months
|
Rate of participants with in-hospital mortality |
Through study completion, an average of 6 months
|
|
Mortality
Prazo: At 1, 3, and 6 months after CO poisoning
|
Number of participants with all cause mortality |
At 1, 3, and 6 months after CO poisoning
|
|
Mortality
Prazo: At 1, 3, and 6 months after CO poisoning
|
Rate of participants with all cause mortality |
At 1, 3, and 6 months after CO poisoning
|
|
Length of stay in intensive care unit and hospital
Prazo: Through study completion, an average of 6 months
|
Length of stay in intensive care unit and hospital |
Through study completion, an average of 6 months
|
|
Pneumonia
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Pneumonia
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Shock
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Shock
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L. |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Bradycardia
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with dropped heart rate indicated drug or interventions |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Bradycardia
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with dropped heart rate indicated drug or interventions |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypokalemia
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with serum K concentration <3.0 - 2.5 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypokalemia
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with serum K concentration <3.0 - 2.5 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperkalemia
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with serum K concentration >6.0 - 7.0 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperkalemia
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with serum K concentration >6.0 - 7.0 mmol/L |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperglycemia
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hyperglycemia
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypophosphatemia
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypophosphatemia
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypomagnesemia
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with serum magnesium <0.9 - 0.7 mg/dL |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Hypomagnesemia
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with serum magnesium <0.9 - 0.7 mg/dL |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged prothrombin Time International Normalized Ratio
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged prothrombin Time International Normalized Ratio
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged activated partial thromboplastin time
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Number of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
Prolonged activated partial thromboplastin time
Prazo: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
Rate of participants with >2.5 x upper limit of the normal range and bleeding |
During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
|
|
S100ß (serum)
Prazo: Within 14 days after CO exposure
|
Concentration of S100ß (serum) |
Within 14 days after CO exposure
|
|
Neuronal specific enolase (serum)
Prazo: Within 14 days after CO exposure
|
Concentration of neuronal specific enolase (serum) |
Within 14 days after CO exposure
|
|
Brain magnetic resonance image (MRI)
Prazo: Within 14 days after CO exposure
|
Number of participants with brain injury in brain MRI |
Within 14 days after CO exposure
|
|
Brain magnetic resonance image (MRI)
Prazo: Within 14 days after CO exposure
|
Rate of participants with brain injury in brain MRI |
Within 14 days after CO exposure
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Yong Sung Cha, MD, Wonju Severance Christian Hospital
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- TTM-COHB trial
- CR220011 (Outro identificador: Wonju Severance Christian Hospital)
- 2021-04-043 (Outro identificador: Inha University Hospital)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .